Table 1.
Characteristic | Overall (n=278 642) | Test result | Vaccination status | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Negative (n=139 321) | Positive (n=139 321) | P value | Unvaccinated (n=60 205) | Partially vaccinated (n=37 941) | Fully vaccinated (n=150 966) | Boosted (n=3755) | Other* (n=25 775) | |||
Any comorbidity: | 1 | |||||||||
No | 265 422 (95.3) | 132 711 (95.3) | 132 711 (95.3) | 56 162 (93.3) | 36 040 (95.0) | 145 172 (96.2) | 3706 (98.7) | 24 342 (94.4) | ||
Yes | 13 220 (4.7) | 6610 (4.7) | 6610 (4.7) | 4043 (6.7) | 1901 (5.0) | 5794 (3.8) | 49 (1.3) | 1433 (5.6) | ||
Sex: | 1 | |||||||||
Female | 142 988 (51.3) | 71 494 (51.3) | 71 494 (51.3) | 29 447 (48.9) | 19 022 (50.1) | 79 594 (52.7) | 2078 (55.3) | 12 847 (49.8) | ||
Male | 135 654 (48.7) | 67 827 (48.7) | 67 827 (48.7) | 30 758 (51.1) | 18 919 (49.9) | 71 372 (47.3) | 1677 (44.7) | 12 928 (50.2) | ||
Type of test: | 1 | |||||||||
RT-PCR | 120 420 (43.2) | 60 210 (43.2) | 60 210 (43.2) | 30 218 (50.2) | 16 362 (43.1) | 58 973 (39.1) | 2637 (70.2) | 12 230 (47.4) | ||
Antigen | 158 222 (56.8) | 79 111 (56.8) | 79 111 (56.8) | 29 987 (49.8) | 21 579 (56.9) | 91 993 (60.9) | 1118 (29.8) | 13 545 (52.6) | ||
Mean (SD) week of diagnosis | 17.4 (4.9) | 17.4 (4.9) | 17.4 (4.9) | 1 | 14.3 (6.9) | 17.5 (3.9) | 18.7 (3.2) | 22.6 (4.4) | 16.5 (5.2) | |
Age group (years): | 0.82 | |||||||||
3-11 | 145 705 (52.3) | 72 822 (52.3) | 72 883 (52.3) | 39 390 (65.4) | 23 460 (61.8) | 66 831 (44.3) | 277 (7.4) | 15 747 (61.1) | ||
12-17 | 132 937 (47.7) | 66 499 (47.7) | 66 438 (47.7) | 20 815 (34.6) | 14 481 (38.2) | 84 135 (55.7) | 3478 (92.6) | 10 028 (38.9) | ||
Time since second dose of vaccine†: | (n=150 966) | (n=77 557) | (n=73 409) | <0.001 | ||||||
<60 days | 72 515 (48.0) | 39 951 (51.5) | 32 564 (44.4) | - | - | 72 515 (48.0) | - | - | ||
≥60 days | 78 451 (52.0) | 37 606 (48.5) | 40 845 (55.6) | - | - | 78 451 (52.0) | - | - |
RT-PCR=reverse transcription polymerase chain reaction; SD=standard deviation.
Includes participants who were vaccinated in the two weeks before their test, those who received another vaccine, and those with inconsistent or incomplete vaccination data.
In fully vaccinated participants.